抗前列腺癌雄激素受体拮抗剂研究进展及市场分析  

Research Progress and Market Analysis of Androgen Receptor Antagonists for the Treatment of Prostate Cancer

作　　者：王红莲 王宁宁 褚定军 WANG Honglian;WANG Ningning;CHU Dingjun(Aurisco Pharmaceutical Co.,Ltd.,Taizhou 317200,China)

机构地区：[1]奥锐特药业股份有限公司,浙江台州317200

出　　处：《药学进展》2023年第8期617-625,共9页Progress in Pharmaceutical Sciences

摘　　要：前列腺癌是男性常见肿瘤。雄激素受体(androgen receptor,AR)是雄激素与前列腺癌细胞结合、发挥激素生物活性、促进前列腺癌组织生长的必要物质。目前AR拮抗剂是前列腺癌主要治疗药物,恩扎卢胺等第2代AR拮抗剂已获批上市,市场关注度高。综述抗前列腺癌AR拮抗剂研究进展,并对市场销售情况进行分析。Prostate cancer is a common tumor in men.Androgen receptor(AR)is an essential substance for androgen to bind to prostate cancer cells,exert hormone biological activity,and promote the growth of prostate cancer tissue.At present,AR antagonists are the main therapeutic drugs for prostate cancer.The second-generation AR antagonists such as enzalutamide have been approved with much attention from the market.This paper reviews the research progress of AR antagonists for the treatment of prostate cancer,and analyzes their market sales.

关 键 词：前列腺癌 雄激素受体 市场销售 生产企业 

分 类 号：R979.1[医药卫生—药品]